Fortress Biotech (FBIO) Investor presentation summary

Market position and financial highlights

• Commercial-stage pharmaceutical company focused on proprietary dermatology products in a $5.8B market, with 2025 net product revenues of $61M and adjusted EBITDA of $2.9M.

• Market cap of $195M, 27.5M shares outstanding, and $24.1M in cash as of 12/31/2025.

• DERM stock added to the Russell 2000 & 3000 indexes in June 2025.

Leadership and commercial infrastructure

• Senior management team with decades of dermatology and pharmaceutical experience, including key roles at Medicis and Bausch Health.

• Sales force averages 9 years of dermatology experience, with 280 years combined, covering 87% of oral rosacea prescriptions.

• Unique incentive programs and equity rewards drive sales performance.

Product portfolio and growth drivers

• Five core dermatology brands, with Emrosi® as the key growth driver, launched April 2025.

• Emrosi® demonstrated head-to-head superiority over Oracea® in Phase 3 trials and is positioned to become the new standard of care for rosacea.

• Other brands include Qbrexza, Amzeeq, Accutane, and Fzilxi, targeting acne, rosacea, and hyperhidrosis.